Toll-like Receptor 4 Modulation as a Strategy to Treat Sepsis

Xavier Wittebole(Cliniques Universitaires Saint-Luc), Pierre‐François Laterre(Cliniques Universitaires Saint-Luc), Diego Castanares‐Zapatero(Cliniques Universitaires Saint-Luc)
Mediators of Inflammation
January 1, 2010
10.1155/2010/568396
Cited by 142

Related Papers

Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
|New England Journal of Medicine|2001|6.1k
High-Flow Oxygen through Nasal Cannula in Acute Hypoxemic Respiratory Failure
|New England Journal of Medicine|2015|2.4k
Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017
|JAMA|2020|1k
Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of Death
|New England Journal of Medicine|2005|890
Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe Sepsis
|JAMA|2013|797